192 related articles for article (PubMed ID: 32518053)
41. PASH, PAPASH, PsAPASH, and PASS: The autoinflammatory syndromes of hidradenitis suppurativa.
Garcovich S; Genovese G; Moltrasio C; Malvaso D; Marzano AV
Clin Dermatol; 2021; 39(2):240-247. PubMed ID: 34272017
[TBL] [Abstract][Full Text] [Related]
42. Renal involvement as a potential feature of pyogenic arthritis, pyoderma gangrenosum, and acne syndrome with E250K mutation of PSTPIP1 gene.
Zhao R; Novice T; Konda S
JAAD Case Rep; 2023 Feb; 32():48-51. PubMed ID: 36660269
[No Abstract] [Full Text] [Related]
43. Tildrakizumab in the treatment of PASH syndrome: A potential novel therapeutic target.
Kok Y; Nicolopoulos J; Varigos G; Howard A; Dolianitis C
Australas J Dermatol; 2020 Aug; 61(3):e373-e374. PubMed ID: 32285437
[No Abstract] [Full Text] [Related]
44. Remission of Refractory PASH Syndrome Using Ixekizumab and Doxycycline.
Gul MI; Singam V; Hanson C; Neill BC; Aires DJ; Rajpara AN
J Drugs Dermatol; 2020 Nov; 19(11):1123. PubMed ID: 33196740
[No Abstract] [Full Text] [Related]
45. Pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome in end-stage renal disease successfully treated with adalimumab.
De Wet J; Jordaan HF; Kannenberg SM; Tod B; Glanzmann B; Visser WI
Dermatol Online J; 2017 Dec; 23(12):. PubMed ID: 29447652
[TBL] [Abstract][Full Text] [Related]
46. Overall and subgroup prevalence of pyoderma gangrenosum among patients with hidradenitis suppurativa: A population-based analysis in the United States.
Tannenbaum R; Strunk A; Garg A
J Am Acad Dermatol; 2019 Jun; 80(6):1533-1537. PubMed ID: 30738122
[TBL] [Abstract][Full Text] [Related]
47. Difficult and rare forms of acne.
Dessinioti C; Katsambas A
Clin Dermatol; 2017; 35(2):138-146. PubMed ID: 28274350
[TBL] [Abstract][Full Text] [Related]
48. PASH syndrome associated with osteopoikilosis.
Gracia-Cazaña T; Frias M; Roselló R; Vera-Álvarez J; Gilaberte Y
Int J Dermatol; 2015 Sep; 54(9):e369-71. PubMed ID: 26175185
[No Abstract] [Full Text] [Related]
49. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen.
Shenefelt PD
Cutis; 1996 May; 57(5):315-9. PubMed ID: 8726710
[TBL] [Abstract][Full Text] [Related]
50. Concurrent hidradenitis suppurativa, inflammatory acne, dissecting cellulitis of the scalp, and pyoderma gangrenosum in a 16-year-old boy.
Koshelev MV; Garrison PA; Wright TS
Pediatr Dermatol; 2014; 31(1):e20-1. PubMed ID: 24118007
[TBL] [Abstract][Full Text] [Related]
51. Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor α therapy.
Bruzzese V
J Clin Rheumatol; 2012 Dec; 18(8):413-5. PubMed ID: 23188209
[TBL] [Abstract][Full Text] [Related]
52. Long-term Remission of Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa Syndrome.
Brokamp G; Bechtel M; Chung C
Cutis; 2023 Jun; 111(6):E2-E6. PubMed ID: 37487120
[TBL] [Abstract][Full Text] [Related]
53. Hidradenitis Suppurativa in a Patient with Smith-Magenis Syndrome: A Case Report.
McKenzie SA; Ni CS; Hsiao JL
Cureus; 2019 Jun; 11(6):e4970. PubMed ID: 31453042
[TBL] [Abstract][Full Text] [Related]
54. Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone.
Staub J; Pfannschmidt N; Strohal R; Braun-Falco M; Lohse P; Goerdt S; Leverkus M
J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2243-7. PubMed ID: 25352307
[TBL] [Abstract][Full Text] [Related]
55. A Unified Concept of Acne in the PAPA Spectrum Disorders.
Maitrepierre F; Marzano AV; Lipsker D
Dermatology; 2021; 237(5):827-834. PubMed ID: 32937626
[TBL] [Abstract][Full Text] [Related]
56. Ancient friends, revisited: Systematic review and case report of pyoderma gangrenosum-associated autoinflammatory syndromes.
Saternus R; Schwingel J; Müller CSL; Vogt T; Reichrath J
J Transl Autoimmun; 2020; 3():100071. PubMed ID: 33305249
[TBL] [Abstract][Full Text] [Related]
57. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review.
Hsiao JL; Antaya RJ; Berger T; Maurer T; Shinkai K; Leslie KS
Arch Dermatol; 2010 Nov; 146(11):1265-70. PubMed ID: 21079064
[TBL] [Abstract][Full Text] [Related]
58. Hidradenitis suppurativa and Mediterranean fever gene mutations.
İlgen U; Yayla ME; Eyüpoğlu Ş; Karahan İ
JAAD Case Rep; 2019 Sep; 5(9):792-793. PubMed ID: 31528679
[No Abstract] [Full Text] [Related]
59. Secukinumab for PASS syndrome: A new choice for therapeutic challenge?
Li M; Xiang H; Liang Y; Xue L; Zhou X; Yang L; Liu H; Yang M; Tang J; Li W
Dermatol Ther; 2022 Jul; 35(7):e15507. PubMed ID: 35419914
[TBL] [Abstract][Full Text] [Related]
60. Spectrum of diseases associated with pyoderma gangrenosum and correlation with effectiveness of therapy: New insights on the diagnosis and therapy of comorbid hidradenitis suppurativa.
Fischer AH; Jourabchi N; Khalifian S; Lazarus GS
Wound Repair Regen; 2022 May; 30(3):338-344. PubMed ID: 35385180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
